Role of CHK2 in cancer development

Clinical and Translational Oncology

Volumn 10, Issue 9, 2008, Pages 538-542

  Perona, Rosario ^a,b   Moncho Amor, Verónica ^a,b   Machado Pinilla, Rosario ^a,b   Belda Iniesta, Cristóbal ^a,c   Pérez, Isabel Sánchez ^a  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b CSIC   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

ATM; ATR; Checkpoints; Chemotherapy; CHK2; DNA damage

Indexed keywords

CHECKPOINT KINASE 2; ENZYME INHIBITOR; PROTEIN SERINE THREONINE KINASE;

ANIMAL; DNA DAMAGE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HUMAN; NEOPLASM; PHYSIOLOGY; REVIEW;

ANIMALS; DNA DAMAGE; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES;

EID: 56149125558     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-008-0248-5     Document Type: Article

References (39)

1. Jackson SP (2001) Detecting, signalling and repairing DNA double-strand breaks. Biochem Soc Trans 29:655-661. Review
2. Su TT (2006) Cellular responses to DNA damage: one signal, multiple choices. Annu Rev Genet 40:187-208. Review
3. Sánchez-Pérez I (2006) DNA repair inhibitors in cancer treatment. Clin Transl Oncol 8:642-646. Review
4. O'Driscoll M, Jeggo PA (2006) The role of double-strand break repair-insights from human genetics. Nat Rev Genet 7:45-54
5. Karlsson-Rosenthal C, Millar JB (2006) Cdc25: mechanisms of checkpoint inhibition and recovery. Trends Cell Biol 16:285-292
6. Lee JS, Collins KM, Brown AL et al (2000) hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 404: 201-204
7. Zhang J, Willers H, Feng Z et al (2004) Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol 24:708-718
8. Wang HC, Chou WC, Shieh SY, Shen CY (2006) Ataxia telangiectasia mutated and checkpoint kinase 2 regulate BRCA1 to promote the fidelity of DNA end-joining. Cancer Res 66:1391-1400
9. Zhuang J, Zhang J, Willers H et al (2006) Checkpoint kinase 2-mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous endjoining. Cancer Res 66:1401-1408
10. Tan Y, Raychaudhuri P, Costa RH (2007) Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol Cell Biol 27:1007-1016
11. Bell DW, Varley JM, Szydlo TE et al (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286:2528-2531
12. Li FP, Fraumeni JF Jr., Mulvihill JJ et al (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358-5362
13. Malkin D, Li FP, Strong LC et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238
14. Meijers-Heijboer H, van den Ouweland A, Klijn J et al; CHEK2-Breast Cancer Consortium (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55-59
15. Seppälä EH, Ikonen T, Autio V et al (2003) Germline alterations in MSR1 gene and prostate cancer risk. Clin Cancer Res 9:5252-5256
16. Cybulski C, Górski B, Huzarski T et al (2004) CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75:1131-1135
17. Szymanska-Pasternak J, Szymanska A, Medrek K et al (2006) CHEK2 variants predispose to be nign, borderline and low-grade invasive ovarian tumors. Gynecol Oncol 102:429-431
18. Kilpivaara O, Alhopuro P, Vahteristo P et al (2006) CHEK2 I157T associates with familial and sporadic colorectal cancer. J Med Genet 43:e34
19. Broeks A, de Witte L, Nooijen A et al (2004) Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. Breast Cancer Res Treat 83:91-93
20. Stracker TH, Couto SS, Cordon-Cardo C et al (2008) Chk2 suppresses the oncogenic potential of DNA replication-associated DNA damage. Mol Cell 31:21-32
21. Oldenburg RA, Kroeze-Jansema K, Kraan J et al (2003) The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res 63:8153-8157
22. Ingvarsson S, Sigbjornsdottir BI, Huiping C et al (2002) Mutation analysis of the CHK2 gene in breast carcinoma and other cancers. Breast Cancer Res 4:R4
23. Sallinen SL, Ikonen T, Haapasalo H, Schleutker J (2005) CHEK2 mutations in primary glioblastomas. J Neurooncol 74:93-95
24. Williams LH, Choong D, Johnson SA, Campbell IG (2006) Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers. Clin Cancer Res 12:6967-6972
25. Stawinska M, Cygankiewicz A, Trzcinski R et al (2008) Alterations of Chk1 and Chk2 expression in colon cancer. Int J Colorectal Dis [Epub ahead of print
26. Zhou BB, Chaturvedi P, Spring K et al (2000) Caffeine abolishes the mammalian G(2)/M DNA damage checkpoint by inhibiting ataxia-telangiectasia- mutated kinase activity. J Biol Chem 275: 10342-10348
27. Graves PR, Yu L, Schwarz JK et al (2000) The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 275:5600-5605
28. Busby EC, Leistritz DF, Abraham RT et al (2000) The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 60:2108-2112
29. Wang Q, Fan S, Eastman A et al (1996) UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 88:956-965
30. Tibbetts RS, Brumbaugh KM, Williams JM et al (1999) A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 13: 152-157
31. Koniaras K, Cuddihy AR, Christopoulos H et al (2001) Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 20:7453-7463
32. Janetka JW, Ashwell S, Zabludoff S, Lyne P (2007) Inhibitors of checkpoint kinases: from discovery to the clinic. Curr Opin Drug Discov Dev 10:473-486. Review
33. O'Connor MJ, Martin NM, Smith GC (2007) Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene 26:7816-7824
34. Kawabe T (2004) G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 3:513-519. Review
35. Arienti KL, Brunmark A, Axe FU et al (2005) Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem 48:1873-1885
36. Carlessi L, Buscemi G, Larson G et al (2007) Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol Cancer Ther 6:935-944
37. Ghosh JC, Dohi T, Raskett CM et al (2006) Activated checkpoint kinase 2 provides a survival signal for tumor cells. Cancer Res 66:11576-11579
38. Chen CR, Wang W, Rogoff HA et al (2005) Dual induction of apoptosis and senescence in cancer cells by Chk2 activation: checkpoint activation as a strategy against cancer. Cancer Res 65:6017-6021
39. Antoni L, Sodha N, Collins I, Garrett MD (2007) CHK2 kinase: cancer susceptibility and cancer therapy-two sides of the same coin? Nat Rev Cancer 7:925-936